Photo from academic.microsoft.com
Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond… Click to show full abstract
Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond PD-L1 expression, which is showing inconsistent results across trials.
Keywords:
checkpoint inhibition;
immune checkpoint;
metastatic urothelial;
urothelial cancer
Journal Title: European urology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European urology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!